Some wanted a pill that would work for their own libidos; others were less than thrilled with partners' renewed interest in sex. David Michael Thomas (doctor): Of the thousands of patients that I saw, a few would even come in literally wearing a trench coat and a hat and sunglasses and refuse to give their name. Aaron Spitz (doctor): The only treatments that did work at that time were pretty invasive and pretty scary.
Pfizer dispatched armies of sales reps to coach physicians in how to bring up the then-delicate topic of impotence, and to dish out samples of a tablet that could treat a condition that had confounded men since the dawn of time, eluding an easy remedy. Caplan: I said, You ought to be worried that you're selling a sex pill, and you could get religious or ethical critics. Jennifer Doebler (Pfizer marketing): At the time, the television regulations were such that we would not be allowed to run the ad before 11 'clock at night.
The initial ads—many of the ads—while they were seen as Fildena ads, were actually men's health ads. Steven Lamm (doctor): I think even Pfizer was overwhelmed by the media coverage. McGibney: The study was designed to use basically soft pornography—or maybe even harder pornography, which wasn't really allowed in the U.K. at that time.
Ian Osterloh (Pfizer research and development): At the time, no one really thought, This is fantastic, this is great news, we're really onto something here. The story of the drug that changed sex and made billions. Egan R, Pomeranz H. Fildena (Fildena) Associated Anterior Ischemic Optic Neuropathy.
He also did not develop an erection or participate in any sexual activity and thus no steal phenomenon can be postulated as the cause of the probable hypotensive event to his optic nerve. This is supported by the ability of Fildena to potentiate the hypotensive effects of nitrates. He took his first dose of 50 mg of Fildena citrate in the evening and, within 1 hour, sweating and a severe generalized headache developed.
L. Zhu, J.-Y. Yang, X. Xue et al., A novel phosphodiesterase-5 inhibitor: yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model,” Mechanisms of Ageing and Development, vol. M. A. Baltrons, C. E. Pedraza, M. T. Heneka, and A. García, β-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells,” Neurobiology of Disease, vol. W. L. Bonkale, B. Winblad, R. Ravid, and R. F. Cowburn, Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease,” Neuroscience Letters, vol.
D. Puzzo, Vitolo, F. Trinchese, J. P. Jacob, A. Palmeri, and Arancio, Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity,” The Journal of Neuroscience, vol.
https://medical.mit.edu/
http://www.vitacarepharma.com/
http://www.hcompound.com/
https://www.nap.edu/read/24946/chapter/1
https://medicamentfrance.eu/